Hold Cipla, may test Rs 700: Vijay Chopra

Vijay Chopra of enochventures.com told CNBC-TV18, "Pharmaceutical is coming out of blue and they have started reporting good numbers and all the pharma majors whether it's Cipla, Lupin or Glenmark Pharma or Wockhardt will see some decent numbers. So to my mind pharma has almost bottomed out, there might be some more correction but it is a good time to buy into pharma stocks.""If the investor holds Cipla from one year perspective then the target could be Rs 700. So definitely some more patience is required, hold on to the stock," he added.